IL17A and histiocytic sarcoma: This investigation is comprised of both translational studies and a Phase II, proof‐of‐concept, clinical study which, taken together, suggest an important role for IL‐17A in HS pathogenesis, and indicate a role for IL‐17A‐targeting therapies in the treatment of moderate‐to‐severe HS (see graphical summary; Figure S4).